Our Work

Brighton Collaboration convenes experts around specific work areas to address the needs of the vaccine safety community. Brighton Collaboration sets up working groups to lead focused projects. View the working groups and projects below, and sort them by category. 

(1 - 10 of 10)

November 13, 2023

The Safety Platform for Emergency vACcines (SPEAC) is a Brighton Collaboration project funded in whole by the Coalition for Epidemic Preparedness Innovations (CEPI).[...]

March 12, 2023

On 8 and 9 November 2022, the Maternal Immunization Working Group (MIWG) held an in-person and online hybrid meeting. The objectives of the[...]

February 22, 2021

Within the context of the Covid19 Vaccine Introduction Program (COVIP), the CARESAFE project builds on existing CDC and Task Force for Global Health[...]

December 1, 2020

Rare adverse events following immunization (AEFIs) occurring in <1 per 10,000 vaccine recipients may not be detected in prelicensure clinical trials. The success[...]

September 22, 2020

Effective safety monitoring of COVID-19 vaccines must go beyond the use of passive surveillance, which is typically used to monitor vaccine safety and generate a hypothesis, to the use of active surveillance[...]

July 14, 2020

In recognition of the increasing importance of viral vectors for the development of new vaccines and the need to understand their associated safety[...]

January 1, 2019

Randomised controlled trials (RCTs) are considered the gold standard for assessing the efficacy of drugs prior to their approval for use in the[...]

January 1, 2019

Background: In 2010, a safety signal was detected for narcolepsy following vaccination with Pandemrix, an AS03-adjuvanted monovalent pandemic H1N1 influenza (pH1N1) vaccine. To[...]

January 1, 2019

About Immunization in PregnancyImmunization in pregnancy is a promising public health strategy to reduce illness and death among pregnant women and young infants.[...]

October 31, 2008

The Brighton Collaboration (BC) Viral Vector Vaccines Safety Working Group (V3SWG) was renamed to Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) in July[...]